Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer

7336 Background:Standard therapy for inoperable stage III NSCLC is chemoradiotherapy. But optimal combination of these two modality is not established. To evaluate the efficacy and safety of chemoradiotherapy with a concurrent use of paclitaxel and carboplatin plus thoracic radiation for locally advanced NSCLC. Methods:The study is a phase II multi-institutional trial. Eligible patients had inoperable stage IIIA or IIIB disease, except cases with pleural or pericardial effusion, ECOG performance status 0 or 1, and no previous treatment. Paclitaxel (45 mg/m2) and carboplatin (AUC = 2) were administered every 7 days for 10 weeks. When PR was observed, chemotherapy was extended upto 16 weeks. Radiation therapy were concurrently administered 1.8∼2.0 Gy/day for 5∼7 week (total 60∼65 Gy). Results:Registration has finished on December 2002. Among the 72 patients registared, 68 patients were eligible and toxicity was evaluated for the 68 patients. There were 16 patients with stage IIIA and 52 with stage IIIB dise...